Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 2—February 2017

Risk Factors for Disseminated Coccidioidomycosis, United States

Camila D. Odio1, Beatriz E. Marciano, John N. Galgiani, and Steven M. HollandComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (C.D. Odio, B.E. Marciano, S.M. Holland); University of Arizona College of Medicine, Tucson, Arizona, USA (J.N. Galgiani)

Main Article

Table 2

Patients with disseminated coccidioidomycosis and discrete primary immune deficiencies*

Patient no. (ref)
Age, y/sex
Medical history
Extrapulmonary disease
Method of diagnosis
Genetic findings
HIES, recurrent pneumonia and otitis, skin infections, eczema, thrush
BAL/CSF cultures
STAT3: heterozygous (c.2137G>A)
2 (9)
Not reported
HIES, Staphylococcus. aureus skin and soft tissue infections, recurrent sinus infections, pneumonia
Meningitis, cerebral abscess
Coccidioides Ab, CSF culture
STAT3: heterozygous (p.T412S)
3 (10)
11 mo: Mycobacterium chelonei pneumonia 22 y; disseminated M. kansasii
Osteomyelits, lymphadenitis
Coccidioides Ab level, lymph node biopsy
IFN-γR1: deficiency (c.818del4fs)
4 (11)†
11 y: Salmonella serogroup D lymphadenitis
Diffuse lymphadenitis
Coccidioides IgM and IgG, lymph node biopsy
IL-12Rβ1: homozygous (p.C186Y)
5 (11)
No other significant history
Osteomyelitis, lymphadenitis, nasal lesion,
Lymph node, nasal lesion, bone biopsies
IL-12Rβ1: homozygous (p.C186Y)
No other significant history
Osteomyelitis, soft tissue
BAL cultures, bone and soft biopsies
IL-12Rβ2: heterozygous (p.C101Y)
7 (12)
14 y: extensive, persistent tinea capitis and kerion caused by Trichophyton tonsurans
Osteomyelitis, soft tissue, cutaneous lesions
Coccidioides Ab, skin biopsy
STAT1: gain of function mutation
8 (12) 9.5/F White No other significant history Osteomyelitis, cerebral lesions, intrathoracic lymphadenitis Yes Coccidioides Ab STAT1: gain of function mutation (p.A267V)

*Ab, antibody; BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; HIES, hyperimmunoglobulin E (Job’s) syndrome; ref, reference.
†Patients 4 and 5 are siblings, and their parents are first cousins.

Main Article

  1. Centers for Disease Control and Prevention (CDC). Increase in reported coccidioidomycosis—United States, 1998-2011. MMWR Morb Mortal Wkly Rep. 2013;62:21721.PubMedGoogle Scholar
  2. Valdivia  L, Nix  D, Wright  M, Lindberg  E, Fagan  T, Lieberman  D, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis. 2006;12:95862. DOIPubMedGoogle Scholar
  3. Ampel  NM, Giblin  A, Mourani  JP, Galgiani  JN. Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clin Infect Dis. 2009;48:1728. DOIPubMedGoogle Scholar
  4. Galgiani  JN, Ampel  NM, Blair  JE, Catanzaro  A, Geertsma  F, Hoover  SE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e11246. DOIPubMedGoogle Scholar
  5. Crum  NF, Ballon-Landa  G. Coccidioidomycosis in pregnancy: case report and review of the literature. Am J Med. 2006;119:993.e117. DOIPubMedGoogle Scholar
  6. Bercovitch  RS, Catanzaro  A, Schwartz  BS, Pappagianis  D, Watts  DH, Ampel  NM. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis. 2011;53:3638. DOIPubMedGoogle Scholar
  7. US Census Bureau. State & county QuickFacts [cited 2013 Sep 30].
  8. Noble  JA, Nelson  RG, Fufaa  GD, Kang  P, Shafir  SC, Galgiani  JN. Effect of geography on the analysis of coccidioidomycosis—associated deaths, United States. Emerg Infect Dis. 2016;22:18213. DOIPubMedGoogle Scholar
  9. Powers  AE, Bender  JM, Kumánovics  A, Ampofo  K, Augustine  N, Pavia  AT, et al. Coccidioides immitis meningitis in a patient with hyperimmunoglobulin E syndrome due to a novel mutation in signal transducer and activator of transcription. Pediatr Infect Dis J. 2009;28:6646. DOIPubMedGoogle Scholar
  10. Vinh  DC, Masannat  F, Dzioba  RB, Galgiani  JN, Holland  SM. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis. 2009;49:e625. DOIPubMedGoogle Scholar
  11. Vinh  DC, Schwartz  B, Hsu  AP, Miranda  DJ, Valdez  PA, Fink  D, et al. Interleukin-12 receptor β1 deficiency predisposing to disseminated Coccidioidomycosis. Clin Infect Dis. 2011;52:e99102. DOIPubMedGoogle Scholar
  12. Sampaio  EP, Hsu  AP, Pechacek  J, Bax  HI, Dias  DL, Paulson  ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J Allergy Clin Immunol. 2013;131:162434. DOIPubMedGoogle Scholar
  13. Magee  DM, Cox  RA. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect Immun. 1996;64:360913.PubMedGoogle Scholar
  14. Ampel  NM, Nesbit  LA, Nguyen  CT, Chavez  S, Knox  KS, Johnson  SM, et al. Cytokine profiles from antigen-stimulated whole-blood samples among patients with pulmonary or nonmeningeal disseminated coccidioidomycosis. Clin Vaccine Immunol. 2015;22:91722. DOIPubMedGoogle Scholar
  15. Kuberski  TT, Servi  RJ, Rubin  PJ. Successful treatment of a critically ill patient with disseminated coccidioidomycosis, using adjunctive interferon-gamma. Clin Infect Dis. 2004;38:9102. DOIPubMedGoogle Scholar

Main Article

1Current affiliation: Yale–New Haven Hospital, New Haven, Connecticut, USA.

Page created: January 12, 2017
Page updated: January 12, 2017
Page reviewed: January 12, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.